Scarica l'app Stockscreener
0.0002
0.00%
0.00
Effector Therapeutics Inc Borsa (EFTR) Ultime notizie
Christopher B. “Chris” Ehrlich, MBA (D’92) – Office of the Dean - Geisel School of Medicine at Dartmouth
TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care - CancerNetwork
PD-1 and PD-L1 Inhibitors Market Expands Rapidly Amid Rising Cancer Burden and Immunotherapy Adoption - openPR.com
Dania Therapeutics identifies new WNK1 inhibitors - BioWorld MedTech
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer - PNAS
PD-1 and PD-L1 Inhibitors Competitor Landscape Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Compass Therapeutics, Aurigene Discovery Tech - The Globe and Mail
eFFECTOR Therapeutics Faced Investigation Over Non-Compliance with Nasdaq and Delisting - TradingView
Fate Therapeutics Announces Phase 1 Data Presentation of - GlobeNewswire
RNA Targeted Therapeutics Market to See Booming Growth - openPR.com
eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity - The Globe and Mail
Biopharma Dealmaking Quarterly Statistics, Q2 2013 - insights.citeline.com
Small-molecule RNA therapeutics to target prostate cancer - ScienceDirect.com
eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting - Barchart.com
Tech-Enabled, Human-Centered: TELUS Digital and Ryan Strategic Advisory Reveal New Trust, Safety & Security Priorities for 2025 - The Globe and Mail
PD-1 and PD-L1 Inhibitors Market Report- Expansive Coverage on the Profit Sources - openPR.com
The Chlamydia effector Dre1 binds dynactin to reposition host organelles during infection - ScienceDirect.com
PD-L1 Non-small Cell Lung Cancer Treatment Market Size in 7MM - openPR.com
Global Equity Markets Slide on US Tariff Concerns - The Globe and Mail
Marjorie Taylor Greene Is Buying Up Beaten-Down Tesla Stock. Should You? - The Globe and Mail
Press Release Service: Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference - CRISPR Medicine News
News: CMN Weekly (28 February 2025)Your Weekly CRISPR Medicine News - CRISPR Medicine News
Your Ford Stock Dividend Could Be at Risk If Trump Goes Ahead with Tariffs - The Globe and Mail
Map Kinase Interacting Serine Protein Kinase 1 Market Enabling Agile and Scalable Business Models in the Digital Age - ExpressVartha
Best Statistical RNA Targeted Therapeutics Market Growth Set - openPR
eFFECTOR Therapeutics (EFTR) Projected to Post Earnings on Friday - Defense World
Atomwise Appoints Steve Worland, Ph.D. as Chief Executive Officer - Business Wire
Sarah Larson, MD, on Evaluating Lyell’s CAR-T IMPT-314 in LBCL - CGTLive®
Anakinra Used in a Patient with Diffuse Large B-Cell Lymphoma and Steroid-Refractory Immune Effector Cell–Associated Neurotoxicity Syndrome: Case Report - Journal of Hematology Oncology Pharmacy
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Structure Therapeutics selects lead oral DACRA for obesity - BioWorld MedTech
The Effector Functions of AntibodiesDaëron2024Immunological Reviews - Wiley Online Library
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO - GlobeNewswire
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board - Newsfile
The 2024 Biotech Graveyard - Fierce Biotech
Non-COVID mRNA Vaccine and Therapeutics Market Expected to Reach $1,684.80 Million by 2031 - WhaTech
mRNA Treatment Market Exclusive Report 2024-2031 - InsightAce Analytic
Rahul Banerjee: Multicenter description of immune effector cell-associated enterocolitis as a novel toxicity of CAR T-cell therapy in multiple myeloma - Oncodaily
Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections - PNAS
Keto diet plus experimental drug may shrink pancreatic tumors - Healio
Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer - PR Newswire
EFFECTOR Therapeutics to Participate in Upcoming Investor Conference - MarketScreener
A Ketogenic Diet Could Improve the Response to Pancreatic Cancer Therapy - Cancer Health
FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer - Business Wire
Policy and perspective on outpatient programs for autologous hematopoietic cell transplantation and immune-effector cell therapy administration - Frontiers
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off - Yahoo Finance
Two healthcare SPACs go public, with several more on the hunt for deals - Endpoints News
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 - GlobeNewswire
StockWatch: Layoffs, ARK Selloff Sink Ginkgo Bioworks - Genetic Engineering and Biotechnology News
Calif. biotech company that raised $325 million shuts down, lays off all workers - SFGATE
eFFECTOR Therapeutics to wind down operations and delist from Nasdaq - Investing.com
Repair of the Infarcted Heart: Cellular Effectors, Molecular Mechanisms and Therapeutic Opportunities - American Heart Association Journals
Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation - ACS Publications
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer - GlobeNewswire
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Glis2 is an early effector of polycystin signaling and a target for therapy in polycystic kidney disease - Nature
Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses | British Journal of Cancer - Nature
Harnessing Microbial Effectors for Macrophage-Mediated Drug Delivery - ACS Publications
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference - Stock Titan
Therapeutic prime/pull vaccination of HSV-2-infected guinea pigs with the ribonucleotide reductase 2 (RR2) protein and CXCL11 chemokine boosts antiviral local tissue-resident and effector memory CD4+ and CD8+ T cells and protects against recurrent genit - ASM Journals
eFFECTOR Therapeutics Announces Topline Results of Phase 2 - GlobeNewswire
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances - Citeline News & Insights
Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities - Frontiers
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference - Yahoo Finance
eFFECTOR Therapeutics Announces Reverse Stock Split - GlobeNewswire
Oncternal Therapeutics Proposes Protocol Changes Following Death of Patient Treated With CAR-T Therapy ONCT-808 in Phase 1/2 Trial - CGTLive®
Kinoteck Therapeutics reports new RSK-2 inhibitors - BioWorld Online
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session - Investing.com UK
Marengo Therapeutics and Kings College London Announce Publication in Science Advances Highlighting the Discovery of a New Approach to T Cell Activation - PR Newswire
Axcella gets the ax: Flagship-founded biotech closes doors after 12-year run - Fierce Biotech
Zotatifin Triplet Gains FDA Fast Track Status in ER+/HER2- Breast Cancer - Targeted Oncology
The role of STRIs in cancer - Drug Target Review
eFFECTOR to Present New Clinical Data from Dose Escalation - GlobeNewswire
BioTechnology Innovators Honored in 3rd Annual BioTech Breakthrough Awards Program - Yahoo Finance
Engineering Clinically Relevant Probiotics with Switchable “Nano-Promoter” and “Nano-Effector” for Precision Tumor Therapy - Wiley
1.38%
0.27%
Capitalizzazione:
|
Volume (24 ore):